Treatment Modification to Reduce Symptom Burden in Hemodialysis

The Rogosin Institute

Status: Completed

Conditions: End Stage Renal Disease

Treatments: Other: Treatment modification

Study type: Interventional

Funder types: Other

Identifiers

NCT01775800

1207012494

Details and patient eligibility

About

Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects. Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.

Enrollment: 16 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• hemodialysis patient
• transplant ineligible

Exclusion criteria

• dementia
• unable to answer questionnaires for any reason

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

16 participants in 2 patient groups

Treatment modification

Experimental group

Description:

Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus.

Treatment:

Other: Treatment modification

Usual care

No Intervention group

Description:

Patients will receive the usual hemodialysis care with no modifications